Boehringer Ingelheim Appoints New Greater China CEO Amid $5.7 Billion R&D Push

On October 17, the official WeChat account of “Boehringer Ingelheim China” announced that Mohammed Tawil will succeed Dong Bowen (Dr. Pavol Dobrocky) as President and Chief Executive Officer of Boehringer Ingelheim Greater China (covering mainland China, Hong Kong [China], and Taiwan [China]), effective January 1, 2024.

According to available information, Dong Bowen joined Boehringer Ingelheim in 1998. He has served as the head of business operations and branch offices at the company’s Slovakian subsidiary, Vienna Central Region, and Russian subsidiary, and also acted as the leader of the global regional integration management project.

In 2020, Dong Bowen came to China to serve as the General Manager of Human Pharmaceuticals at Boehringer Ingelheim Greater China. On March 1, 2023, he officially assumed the role of President and CEO of Boehringer Ingelheim Greater China (covering mainland China, Hong Kong [China], and Taiwan [China]).Amidst the challenges posed by the COVID-19 pandemic and volume-based procurement, he led his team to successfully transform and implement a new business and organizational strategy. These efforts enhanced patient access to innovative medicines, expanded innovative collaborations, and built an ecosystem for whole-disease management. Additionally, Boehringer Ingelheim China’s first digital product—the Digital Home Rehabilitation Platform for Stroke—was launched. During this period, Dong Bowen demonstrated exceptional leadership and resilience.

Mohammed Tawil currently serves as President, Chief Executive Officer, and Head of Human Pharma for the IMETA region (India, Middle East, Turkey, and Africa) at Boehringer Ingelheim. With over two decades of experience at Boehringer Ingelheim, Tawil possesses extensive expertise in leveraging data and insights to define overall business strategic direction.He joined Boehringer Ingelheim in 1995 as a Medical Representative for the Jordan branch. Over the next two decades, he successively held key positions in the Near East, Middle East, and North Africa.

In 2017, he relocated to the company’s headquarters to serve as Regional Business Manager for the Human Pharmaceuticals Division, overseeing markets in China, Mexico, Brazil, and South America. He has held his current position since 2020. Throughout his career, he has played a pivotal leadership role in prioritizing and upholding the company’s core values, while demonstrating a strong passion for employee engagement and talent development. He is renowned for establishing clear direction, articulating an inspiring vision, and exercising decisive leadership.

Mohammed Tawil stated, “I am thrilled to take up my post in the Greater China region and look forward to working with my colleagues here to drive the continued growth of our business. Greater China is a dynamic region and one of Boehringer Ingelheim’s key markets and hubs for innovation. I am confident that the innovative products and solutions we are set to launch in the coming years will contribute to further improving human and animal health in the region.”

On October 19, 2023, Boehringer Ingelheim announced that EI-001, a Class 1 innovative drug developed in collaboration with Elixiron Immunotherapeutics for the treatment of vitiligo, had received approval from China’s National Medical Products Administration (NMPA) to commence clinical trials (IND). Previously, EI-001 had completed Phase I clinical studies in healthy volunteers overseas. This NMPA clinical trial approval marks another milestone in the drug’s clinical development.

In this collaborative development, Boehringer Ingelheim Biopharmaceuticals provided Anlicixirong with end-to-end services for the EI-001 project, encompassing cell line construction, manufacturing process and formulation development, cGMP production of drug substance and drug product, and preparation of CMC regulatory submission documents. The construction of high-yielding and stable cell lines is the first step in biologic CMC development; their quality is critical to ensuring drug yield, quality consistency, stability, and scalability, thereby directly impacting subsequent product development and commercial supply.

The Boehringer Ingelheim cell line and its process platform employed in Project EI-001, leveraging their robust process performance, mature process platform, and profound technical expertise, continuously create value for biologics and benefit patients. They facilitate the rapid advancement of early-stage clinical development of innovative drugs, laying a solid foundation for late-stage CMC development, as well as product launch and commercial supply.

Since the beginning of this year, Boehringer Ingelheim has maintained a consistently positive performance. According to the first-half 2023 results released in August, net sales for the first half increased by 9.7% to €12.2 billion. Of this, net sales from the Human Pharmaceuticals business rose by 11.3% year-on-year to €9.6 billion, while net sales from the Animal Health business grew by 3.8% year-on-year to €2.5 billion.

Boehringer Ingelheim’s human pharmaceuticals business accounts for the majority of its total revenue. In the first half of this year, growth in this segment was primarily driven by the strong performance of the Jardiance® family (€3.5 billion) and the respiratory disease medication Ofev® (€1.7 billion). With ongoing regulatory progress for new indications in chronic kidney disease, sales of Jardiance® are expected to increase further.

In terms of R&D, brigimadlin, an MDM2-p53 agonist in the oncology field, has entered pivotal clinical studies for the treatment of dedifferentiated liposarcoma. Two other investigational therapies in the oncology pipeline (zongertinib, also known as BI 1810631, and BI 764532) are also accelerating their clinical development processes.

The PDE4B inhibitor BI 1015550 is currently undergoing two Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis. In the clinical trial of BI 1015550 for IPF, patient enrollment has far exceeded the planned schedule.

In addition, Boehringer Ingelheim has entered into 15 new collaborations in the fields of oncology immunotherapy, pulmonary fibrosis, and retinal diseases, continuously expanding its product portfolio.

Boehringer Ingelheim expects to achieve further progress in the field of innovation this year, including the release of results from a Phase III clinical trial evaluating empagliflozin in patients after myocardial infarction, as well as the submission of a registration application for Ofev® in the treatment of interstitial lung disease in adolescents aged 6–17 years.

On October 16, the 2023 Shanghai International Biopharma Week, themed “Collaborating for a Future Full of Vitality,” officially kicked off. In an interview with Shanghai Securities News on the sidelines of the event, Zang Yuguo, General Manager of Boehringer Ingelheim China’s Biopharmaceuticals Division, stated that the company plans to invest more than RMB 4 billion in research and development in China over the next five years. Specifically, its Human Pharmaceuticals business is expected to achieve over 30 regulatory approvals by 2029. Meanwhile, its Animal Health division anticipates that more than 15 new products and new indications will be approved for launch in China within the next five years, covering key species among both livestock and companion animals.